Calidi Biotherapeutics, Inc. (CLDI) Ownership
CLDI ownership summary
as of October 17, 2026- Institutions
- 1.0% of shares outstanding
- Insiders
- 0.61% of shares outstanding
- Shares outstanding
- 3.7M
- Float
- 2.6M shares available to trade
- Short interest
- 6.38% 233K shares short
- Days to cover
- 1.12 short interest up 0.9% vs prior month
- Institutions 1.00%
- Insiders 0.61%
- Other investors 98.39%
CLDI insider transactions
latest 5| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-12 | Allan Camaisa | Sell | $1.46 | 850 | $1,241 |
| 2025-08-21 | Andrew C Jackson | Buy | $2.00 | 2,500 | $5,000 |
| 2025-08-21 | Eric E Poma | Buy | $2.00 | 25,000 | $50,000 |
| 2025-08-21 | James A Schoeneck | Buy | $2.00 | 75,000 | $150,000 |
| 2025-08-21 | Scott Leftwich | Buy | $2.00 | 125,000 | $250,000 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CLDI shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CLDI
Institutional investors own 1.0% of Calidi Biotherapeutics's shares and insiders 0.61%. Short interest is 6.38% of the float, or 1.12 days of average trading volume. The share count rose 2,927.5% since 2021.
Related: CLDI analyst forecast, CLDI key metrics. See the CLDI stock overview for the latest quote and news.
CLDI ownership FAQ
What percentage of Calidi Biotherapeutics is owned by institutions?
Institutions hold 1.0% of Calidi Biotherapeutics's shares outstanding; insiders hold 0.61%.
What is Calidi Biotherapeutics's short interest?
233K shares of Calidi Biotherapeutics were sold short, 6.38% of the float; at the average daily volume it would take 1.12 days to cover.
Are insiders buying or selling Calidi Biotherapeutics?
Of the latest 5 reported insider transactions in Calidi Biotherapeutics (since August 21, 2025), 4 were purchases and 1 were sales.
How many shares of Calidi Biotherapeutics are outstanding?
Calidi Biotherapeutics has 3.7M shares outstanding, of which 2.6M are in the public float.